Key result
DOACs and VKAs pose unique management challenges for AF in hemodialysis given limited randomized data.
Why the study?
Data from prospective randomised trials regarding oral anticoagulation in hemodialysis patients with AF are limited, leading to great variability in clinical practice and guideline recommendations.
Does the use of direct oral anticoagulants compared to vitamin K antagonists improve outcomes in patients with atrial fibrillation on chronic hemodialysis?
Population
Patients with AF and CKD undergoing hemodialysis
Comparison
VKA vs DOAC
Design
Review
Authors
Loading...
Highlights ongoing uncertainty in stroke prevention for hemodialysis patients with AF; leaves open the optimal.
Does the use of direct oral anticoagulants compared to vitamin K antagonists improve outcomes in patients with atrial fibrillation on chronic hemodialysis?
This review highlights the limited prospective data and resulting practice variability regarding the use of DOACs versus VKAs for stroke prevention in hemodialysis patients with atrial fibrillation.
Niehues et al. (2023) conducted a review in Atrial fibrillation in patients on chronic hemodialysis. Direct oral anticoagulants (DOACs) vs. Vitamin K antagonists (VKA) was evaluated. Direct oral anticoagulants and vitamin K antagonists present unique management challenges in hemodialysis patients with atrial fibrillation, with limited prospective randomized data to guide therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: